Biotech Values

[genisi]

This way they only need to market one product and put to rest the issue of a lower dose working as well. So I see it as a very modest positive.

Looking at their patent of 4-aminopyridine, it doesn't seem to cover the 5 mg dose. So perhaps one less threat from a possible lower dose generic is positive.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,007,826.PN.&OS=PN/8,007,826&RS=PN/8,007,826